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Summary
 
Mice intranasally inoculated with influenza A/X-31 are protected against a subsequent intrace-
rebral challenge with the neurovirulent influenza A/WSN and this heterotypic protection is
 
mediated by CD8
 
1
 
 cytotoxic T lymphocytes. We have studied the kinetics of this secondary
immune response and found that despite the elimination of replication-competent virus by day
10, we were able to recover activated influenza-specific cytotoxic T lymphocytes (CTLs) that
killed freshly ex vivo from the brains of mice for at least 320 d after the intracerebral inocula-
tion. The activated antiviral CTLs expressed high levels of the early activation marker CD69,
suggesting continuing TCR signaling despite a lack of viral protein and major histocompatibil-
ity complex staining by immunohistochemistry in the brain parenchyma and barely detectable
levels of viral nucleic acid by single and two-step reverse transcription PCR. Local persistence
of activated lymphocytes may be important for efficient long-term responses to viruses prone
to recrudesce in sites of relative immune privilege.
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O
 
ne outcome of inefficient central nervous system
(CNS)
 
1
 
 immunity is virus persistence (for review see
reference 1) and the diseases increasingly associated with it
(2, 3). Terminally differentiated cells such as neurons are
good long-term hosts for viruses since they do not readily
undergo either viral or CTL-mediated apoptosis (4) and
they can escape CTL detection due to low levels of surface
MHC molecules (5). We have recently shown that al-
though influenza virus infection confined to the brain pa-
renchyma is associated with marked inflammation, it is
weakly immunogenic even if the virus actively replicates
(6, 7). The lack of lymphoid tissue and resident dendritic
cells (for review see reference 8), the exclusion of lympho-
cytes with a naive phenotype (9, 10), and the lack of well-
defined lymphatic drainage (for review see reference 11) all
reduce the efficiency of immune responses to virus infec-
tion in the CNS parenchyma. Control of virus infection
largely depends on an influx into the brain of cellular effec-
tors and/or a specific antibody that have been primed sys-
temically. Systemic activation of antiviral CTLs would be
expected in acute encephalitis since systemic infection usu-
ally precedes or accompanies infection in the CNS. But
what provides the stimulus for CNS migration after the pe-
ripheral infection subsides is unknown; the activation state
of most circulating antiviral effectors wanes after systemic
virus has been cleared (indeed some memory cells revert to
a more naive phenotype; reference 12).
Persistent antiviral immunity in the CNS could result ei-
ther from continuing lymphocyte recirculation into the
CNS or from persistence of lymphocytes at the site of ini-
tial inflammation. Recently, memory CTLs have been
shown to persist locally in the lungs after intranasal infec-
tion (13). We now show that after an acute monophasic vi-
ral encephalitis, activated CTLs remain localized to the site
of virus infection long after effective viral clearance. The
persistent CD8
 
1
 
 lymphocytes are not proliferating yet ex-
press high levels of the early activation marker CD69, sug-
gesting continuing lymphocyte interaction with specific
MHC–peptide complexes, despite an absence of detectable
viral protein and undetectable levels of viral nucleic acid.
 
Materials and Methods
 
Mice, Viruses, and Inoculation.
 
6–8-wk-old C57BL/10 mice were
used for experiments. Influenza viruses A/WSN (H1N1) and A/X31
(H3N2) were propagated, titered, and inoculated as previously
described (14).
 
1
 
Abbreviations used in this paper:
 
 CNS, central nervous system; LCMV,
lymphocytic choriomeningitis virus; NP, nucleoprotein.
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Virus Titers and Viral RNA.
 
Replication-competent A/WSN
virus was recovered from infected organs as previously described
(14). cDNA was synthesized from total brain RNA by standard
methods. A 489-bp fragment of the influenza A nucleoprotein (NP)
gene was amplified using the following oligonucleotide primer
pairs and conditions: NP1, 5
 
9
 
-GCATGCAATTCTGCTGCAT-
3
 
9
 
; NP2, antisense 5
 
9
 
-CTCTGCATTGTCTCCGAAG-3
 
9
 
; 5
min at 95
 
8
 
C, followed by 30 1-min cycles of 57, 70, and 94
 
8
 
C.
As a positive control for the cDNA synthesis, we also amplified a
214-bp fragment of murine hypoxanthine guanosine phosphoribosyl
transferase cDNA using the following primer pairs and condi-
tions: 5
 
9
 
-GTAATGATCAGTCAACGGGGGAC-3
 
9
 
; 5
 
9
 
-CCA-
GCAAGCTTGCAACCTTAACCA-3
 
9
 
 at 95
 
8
 
C, followed by 30
1-min
 
 
 
cycles of 55, 70, and 94
 
8
 
C. A 293-bp fragment was also
amplified from one fifth of each of the first set of NP reactions
and their negative, using an additional internal NP primer (NP4,
5
 
9
 
-ATCAACAGAGGGCCTCTGC-3
 
9
 
, with the above NP2
primer) as for the first round reaction.
 
Lymphocyte Cultures.
 
Lymphocyte cultures were maintained
as in reference 6. The NP 366-374–specific CTL clone was de-
rived from an A/X-31–stimulated short-term line by limiting di-
lution using standard methods (15). It responded to influenza A/
WSN and to picomolar concentrations of its NP 366-374 pep-
tide, ASNENMETM.
 
Isolation of Lymphocytes from the Brain and Lung.
 
Terminally anes-
thetized mice were perfused with heparinized PBS
 
 
 
(1 U/ml) via
the left
 
 
 
(for brain) or right (for lungs) cardiac ventricles, and the
organs were harvested into ice-cold 25 mM Hepes-buffered F-10
medium (Life Technologies, Paisley, UK)/10% FCS.
 
 
 
After pre-
mincing the lung samples with scissors to assist homogenization,
the brain and lung samples were homogenized by gentle tritura-
tion through 19- and then 21-gauge needles.
 
 
 
Homogenates (de-
rived from single animals) were then centrifuged in 15-ml conical
tubes at 400 
 
g
 
 (at 4
 
8
 
C) for 7 min and the pellets were resuspended
in 4 ml of
 
 
 
Percoll (Pharmacia, Milton Keynes, UK) solution con-
taining 10% RPMI 
 
3 
 
10 (Life Technologies) and 0.2% bicarbon-
ate (taken as 100% Percoll).
 
 
 
Dilutions of RPMI containing 60,
40, and 0% of the Percoll solution were overlaid.
 
 
 
The discontinu-
ous gradients were centrifuged for 15 min at 1, 000 
 
g
 
 (at 4
 
8
 
C) and
lymphocytes were harvested from the 40–60% interface after first
removing the myelin layer (at the 0–40% interface).
 
 
 
In prelimi-
nary experiments, 
 
.
 
98% of the total recoverable intracerebral T
cells were found at the 40–60% interface (not shown).
 
CTL Assays.
 
Cytotoxic activity was tested in standard 4–5-h
 
51
 
Cr–release assays as previously described (6, 14). The percentage
specific lysis was calculated as 100 
 
3
 
 (release by CTL 
 
2 
 
release
by targets alone)/(release by 2% Triton X-100 
 
2
 
 release by tar-
gets alone). 
 
51
 
Cr release from the targets alone was 5–15% of 
 
51
 
Cr
release with Triton X-100.
 
Limiting Dilution Analysis.
 
Established methods were used
for limiting dilution analysis (12).
 
 
 
Varying numbers of responder
cells (12–24 replicates) pooled from two to six mice were restim-
ulated in IL-2–supplemented medium for 8 d using 1 
 
m
 
M NP
366-374–pulsed irradiated splenic feeder cells (3–4 
 
3 
 
10
 
5
 
 cells/
200-
 
m
 
l well). 
 
51
 
Cr-labeled, peptide-pulsed EL-4
 
 
 
(H-2
 
b
 
) targets
were added to 100 
 
m
 
l of each resuspended replicate well for 5 h at
37
 
8
 
C and the supernatants were assayed for 
 
51
 
Cr release as above.
We designated wells as positive if the cpm released was greater
than the mean plus three standard deviations of the feeder cell
replicates that had only received targets and no effector cells. The
log
 
10
 
 of the proportion of negative wells was plotted against the
input cell number and a line of best fit drawn using the least
squares method.
 
 r
 
2
 
 values were all
 
 
 
.
 
0.93.
 
Flow Cytometry, Cell Sorting, and Immunohistochemistry.
 
Cell sur-
face staining was performed as described in reference 6 using the
following primary antibodies: rat anti–mouse: anti-CD4, KT6-
PE, IgG2a (Serotec, Kidlington, UK); anti-CD8, KT15-FITC,
IgG2a (Serotec); anti-CD62L, biotinylated MEL-14, IgG2a; anti-
CD44, biotinylated IM7.8.1, IgG2b; anti-CD49d, biotinylated
PS/2, IgG2b (16); anti–Mac-1, biotinylated M1/70, IgG2b; anti-
CD25, Quantum red–conjugated 3C7 (Sigma Immunochemicals,
Poole, UK); hamster anti–mouse: anti-CD69, biotinylated H1.2F3,
IgG (PharMingen, San Diego, CA), anti-
 
g/d
 
 TCR mAb, bioti-
nylated GL3, IgG (Serotec). After a 30-min primary incubation
and a wash, the appropriate samples were incubated for 15 min
with streptavidin Quantum red (Sigma Immunochemicals). After
a further wash the samples were immediately analyzed on a Bec-
ton Dickinson (Mountain View, CA) FACSort
 
Ò
 
 instrument using
Cellquest V1.1 software (Becton Dickinson). The combinations
of primary antibodies used provided internal specificity controls.
M1/70 and GL3 staining were negative on brain and spleen sam-
ples (not shown). Changes in cell phenotype consequent upon
the process of cell purification were excluded by mixing brain
cells and splenocytes at the time of homogenization and then
demonstrating that naive cells could be purified by density gradi-
ent centrifugation (Hawke, S., unpublished data; reference 10). In
vivo administration and internal staining of bromodeoxyuridine
(BRDU) with anti-BRDU antibody (Becton Dickinson) was
performed as described previously (17). After perfusion with hep-
arinized PBS, brains from A/X-31 immune animals were cryo-
preserved at the following time points after intracranial challenge
with A/WSN on days 2, 5, 7, 21, 42, 115, 212, and 320 (three
mice at each time point). Immunohistochemistry was performed
exactly as in references 6, 7, and 14 using the following primary
antibodies: rat anti–mouse CD8, YTS 169.4; CD4, GK1.5;
MHC class I (H-2K), M1-42.3.9.8; MHC class II, M5/114.15.2;
B220, RA3-6B2; and rabbit antiinfluenza ribonucleoprotein
(sourced as in reference 7).
 
Results and Discussion
 
After direct inoculation into the lateral cerebral ventricle
of the mouse, the neurovirulent influenza A/WSN (H1N1)
replicates in ependymal cells and then spreads into the brain
parenchyma where it infects neurons (18). In nonimmune
mice, the resulting encephalitis leads to death within 6–8 d.
Earlier immunization with intranasal influenza A/X-31
(H3N2) protects 80% of mice and this “heterotypic” pro-
tection is mediated by CD8
 
1
 
 lymphocytes (14). A sustained
clinical recovery occurs after day 5, and this is coincident
with a marked reduction in recoverable replication-com-
petent virus (14).
We purified lymphocytes from the brains of immune
mice challenged with A/WSN and found that there was
rapid recruitment of CD4
 
1
 
 and CD8
 
1
 
 lymphocytes (Fig. 1
 
a
 
), initially (days 0 and 4) in proportions similar to those
found in peripheral blood or spleen. But from day 4 to day
21 there was a 300-fold increase in the number of CD8
 
1
 
lymphocytes, which then declined exponentially, never
reaching normal levels during the follow-up period (320 d).
Histological analysis, even as late as 320 d after the intrace-
rebral challenge showed CD8
 
1
 
 lymphocytes in the brain,
both within or adjacent to the choroid plexus and scattered
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Figure 1. High frequencies of CD81 T cells are recoverable from the brain for long after A/WSN infection. (a) Cells were purified from the brains of
A/X-31–primed A/WSN-challenged mice at various time points as described in Materials and Methods and used directly in CTL assays without restim-
ulation. Total cell counts (broken line, circles), CD4 (triangles), and CD8 (squares) frequencies are plotted. Each data point represents the means of two sepa-
rate trials with two to eight mice at each time point, except for day 320, which represents a single assay on brain lymphocytes pooled from eight mice.
Standard deviations ,10% are not shown. (b) Lysis of virus-infected (circles) and peptide-pulsed (triangles) EL-4 target cells is titratable and antigen specific
(squares, untreated target cells). Variation between duplicates was ,15%. E/T ratios refer to the ratio of CD81 cells to target cells.
Figure 2. Cryostat coronal brain sections from mice inoculated 5 (a–f ) and 320 (g–l) d previously with intracerebral A/WSN. Day 5: (a) CD81 cells
infiltrating the choroid plexus of the third ventricle (IIIv) and the periaqueductal parenchyma. (b) CD41 cells (c) markedly increased MHC class I expres-
sion in brain parenchyma, (d) increased MHC class II expression predominantly within the inflammation obliterating the lateral ventricle (Lv), (e) B2201
cells in the lateral recess of the third ventricle, and (f) influenza ribonucleoprotein (RNP) expression surrounding the cerebral aqueduct (Aq). Arrow, virus-
infected cell. Day 320: (g) groups of CD81 cells adjacent to the corpus callosum, (h) parenchymal CD41 cell, single CD41 cells in the brain parenchyma
were evident on occasional sections. Lack of MHC class I (i) and II (j) staining in the brain parenchyma. (k) Accumulation of B2201 cells within the
choroid plexus of the lateral ventricle, (j) absence of antiinfluenza RNP staining (periaqueductal region). The ependymal cell loss seen in h, k, and l is
consequent on viral cytopathology. Bar: 50 mm in g and h and 250 mm in the other panels.
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throughout the brain parenchyma (Fig. 2 g). In contrast,
numbers of CD41 cells returned to normal within 28 d, al-
though rare CD41 staining cells were evident in the cho-
roid plexus and even in the brain parenchyma at later time
points (Fig. 2 h). Whether CD41 lymphocytes undergo ap-
optosis in the brain (19), or eventually migrate out of the
brain is unknown. CD41 cells do not contribute to protec-
tion in this system (14). In the acute phase, large aggregates
of B2201 cells were present in the choroid plexus and some
were scattered throughout the brain parenchyma (Fig. 2 e).
At later time points, small aggregations of B2201 cells were
evident adjacent to or within the choroid plexus, but not in
the brain parenchyma (Fig. 2 k compared with reference
20). MHC class I and II molecules were rapidly upregu-
lated in acute A/WSN encephalitis (Fig. 2, b and c, and ref-
erence 14) and then declined to normal levels by days 115
and 320 (Fig. 2, i and j) after inoculation.
We tested the ability of lymphocytes purified from the
brain to kill peptide-pulsed and virus-infected target cells.
By day 7 when the mice were clinically recovering, we
found consistent cytotoxicity immediately ex vivo against
the immunodominant Db-restricted influenza A NP 366–274
peptide (21) and virus-pulsed targets. Surprisingly, this fresh
killing ex vivo was still demonstrable 320 d after clinical re-
covery, which was the last time point examined (Fig. 1 b
and Table 1). This fresh killing was also remarkably consis-
tent when sufficient cells were recovered to test the re-
sponse from individual mice. To compare the secondary
CTL response in another organ, we intranasally inoculated
A/X-31–primed mice with 0.2 hemagglutinating units A/
WSN and purified lung lymphocytes by the same method.
In contrast to the brain, fresh killing by lung lymphocytes
ex vivo was demonstrable from day 4 to day 18, but was
absent at day 33 (Table 1), even though previous work has
Table 1. Long-term Antiviral CTL Response
Day after
intracranial
A/WSN n*
CD81 cell
frequency
mean 6 SD
Maximum
E/T cell ratio
(adjusted for CD81
frequency)
EL-4 targets pulsed with
NP 366-374 proportion
of maximal CTL lysis§
mean 6 SD
A/WSN proportion of
maximal CTL lysis
mean 6 SD
NIL proportion of
maximal CTL lysis
mean 6 SD
Fresh killing from lymphocytes purified from the brain
%‡ % % %i
0 4 9.6 6 2.0 ND ND ND ND
4 3 15.8 6 4.0 3:1 30 6 13 66 6 8 24 6 4
7 4 35.3 6 2.2 7:1 39 6 19 76 6 4 4.6 6 2.3
11 3 70.0 6 4.0 14:1 41 6 30 46 6 4 1.2 6 0.6
18 3 71.0 6 5.7 14:1 55 6 24 35 6 12 1.0 6 0.3
28 3 69.0 6 1.1 14:1 58 6 12 55 6 23 ,1
42 1 52.5 6 7.8 11:1 39 47 ,1
56 3 58.4 6 3.9 12:1 27 6 9 24 6 6 ,1
115 2 33.5 6 5.0 6.7:1 38 6 8 21 6 5 ,1
212 2 27.3 6 10.6 4.3:1 35.2 6 7 24 6 6 ,1
320 1 20 4:1 17 49 ,1
Fresh killing from lymphocytes purified from the lung
0 4 7.7 6 0.5 4:1 ,1 ,1 ,1
4 4 19.0 6 7.0 9.5:1 36 6 12 20 6 6 ,1
11 4 20.6 6 5.8 10.2:1 59 6 34 24 6 10 10 6 5
18 4 21.0 6 6.8 10.5:1 24 6 1 28 6 4 4 6 3
33 4 17.1 6 8.0 8.5:1 3 6 3 1.5 6 0.5 1 6 1
*n, number of assays at each time point. For brain, from days 0 to 56, lymphocytes were purified from individual or pairs of mice before being as-
sayed; from day 115, lymphocytes derived from pools of four to eight mice were assayed. For lung, two separate trials each with two assays at each
time point with two mice in each.
‡CD81 frequency was determined by flow cytometry.
§Each assay included lysis by an NP 336-374–specific CTL clone (clone 1:3) to allow comparison between each assay. Lysis of peptide- or virus-
pulsed targets is expressed as a proportion of maximum killing of peptide- or virus-pulsed targets by clone 1:3.
iProportion of maximal lysis by clone 1:3 of peptide-pulsed targets. Average killing over all assays by clone 1:3 of unpulsed, WSN–, and NP 366-
374–pulsed targets was 2.2 6 2.0, 35 6 13, and 57 6 13 (mean percent specific lysis 6 SD, n 5 17), respectively.
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established that memory cells can be detected at mucosal
sites (after in vitro restimulation) for .1 yr after primary
infection (13). Presumably, the factors that promoted con-
tinuing lymphocyte activation were present in the brain
and not in the lung. Fresh killing wanes at other sites in the
absence of continuing infection (22). We measured the fre-
quency of NP 366-374–specific CTLs at various times after
the intracerebral challenge and found, as expected, a high
frequency of NP-reactive brain lymphocytes as the im-
mune response evolved. (Table 2). Comparison of the NP
366-374–specific CD81 cell frequency in the brain and
splenic CD81CD44hiCD62Llo populations indicated that
the brain was enriched with virus-specific precursors.
Since the frequency of NP 366-374–reactive lympho-
cytes in the brain was high even at day 7, it was possible
that persistently activated extracerebral CD44hiCD62Llo
cells in the A/X-31–primed mice not challenged intracere-
brally might also exhibit fresh killing, and that the activated
cells selectively migrated into the brain, i.e., without re-
quiring activation (9). We therefore cytofluorometrically
sorted CD81 CD62Llo cells from the A/X-31 spleens di-
rectly into microtiter plates and then added the antigen-
pulsed or unpulsed EL-4 targets. No fresh killing of either
was apparent (not shown). This suggests that intracerebral
challenge with A/WSN had led to the reactivation of the
memory population either in the periphery due to the 5-ml
volume of injection used (6) or at the sites of intracerebral
inflammation (cells similarly cloned from the brains of A/
X-31–primed A/WSN-challenged mice killed peptide and
virus-pulsed targets; not shown).
As expected (10), we found that most lymphocytes re-
cruited to the brains of A/X-31–primed A/WSN chal-
lenged mice had a memory/activated phenotype (CD44hi
CD62Llo), whether assessed early or late in the immune re-
sponse. We also found high levels of CD49d on all cells.
CD25 and CD71 were only very weakly expressed on
CD41 or CD81 lymphocytes, if at all. Mac-1 expression
has been reported to be increased, but like others, we
found no evidence of this (10). The activation marker that
most clearly discriminated between peripheral and CNS
lymphocytes was CD69 (Fig. 3 a). Remarkably, CD69 ex-
pression remained high 6 mo after the intracerebral chal-
lenge (Fig. 3 c), indicating that specific viral MHC–peptide
complexes persisted and/or that the activation state had not
been turned off. Only a small proportion of the CD81 cells
were dividing (as measured by BRDU uptake) whether as-
sessed at 3 (not shown) or 6 (Fig. 3 c) mo, possibly because
levels of cytokines such as type 1 interferon (23) had fallen.
This contrasted with the large proportion of CD81 cells
that took up BRDU when pulsed for 6 d after the intrace-
rebral challenge with A/WSN (Fig. 3 b).
Previous work had demonstrated that after intracerebral
inoculation of A/WSN into X-31–primed mice, the virus
replicated to high titers for 5 d, but thereafter declined rap-
idly and was unrecoverable after 6 d (14). In this study we
were again unable to recover replication-competent virus
from brain homogenates on day 7 and 10 by plaque assay
or brain coculture on MDCK cells or by inoculation into
embryonated eggs. Finally, infectious virus was also unre-
coverable from the brains of lethally irradiated (1,000 cGy)
mice 1 and 6 mo after the intracerebral A/WSN challenge.
In the lung, replication-competent virus was recoverable
from only 30% of mice 3 d after the challenge.
What maintains the persistently activated NP-specific
CTL in the brain? Viral antigens have been reported to
persist in the CNS (24, 25), but in our model, viral ribonu-
cleoproteins were undetectable immunohistochemically af-
ter 21 d (days 5 and 320 shown in Fig. 2). We sought viral
mRNA from whole brain cDNA using single-step PCR
and were consistently unable to amplify the influenza nu-
cleoprotein cDNA after 23 d (Fig. 4). This was in contrast
to the slower clearance of viral nucleic acid in other exper-
imental CNS virus infections after adoptive transfer of im-
mune effectors (24–26). To increase the sensitivity of de-
tection, we performed two-step seminested PCR (Fig. 4)
and identified viral nucleic acid in 7 of 24 mice tested from
day 30. At day 115, three of nine mice were positive.
However, NP cDNA was never detected in brain cDNA
by the two-step, seminested PCR in animals sampled after
day 115 or from mice that had received intranasal A/X-31
alone (Table 3). Both products included the NP 366-374
epitope, to which persisting CTLs were reactive. In the
Table 2. NP 366-374–specific CTL Precursor/Effector Cell 
Frequency
Day after
intracranial
A/WSN
Frequency of NP 366-374–reactive CTL precursor
1/brain
lymphocytes
1/brain
CD81 
cells*
1/splenic
mononuclear
cells
1/splenic
CD81
CD62Llo
cells
0 ND ND 8,830 88
ND ND 12,654 126
4 32‡ 3.8 ND ND
25 3.5 ND ND
7 8.4 3.0 ND ND
9.3 3.0 ND ND
11 ,20 ,15 10,305 110
21 10 6.8 15,965 83
49 33.0 19,214 100
42 ,30 ,17 14,975 115
56 10 5.8 ND ND
190 27 8.6 13,819 126
Each frequency (individual assays shown above) was determined for
lymphocytes purified from duplicate or quadruplicate mice.
*96.5 6 1.7% of the CD81 cells purified from the brains of A/WSN-
inoculated mice are CD62Llo (mean 6 SD; n 5 10).
‡The apparent high frequency of NP 366-374–reactive precursors at
day 4 most probably reflects a combination of specific and nonspecific
lysis (see Table 1).
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heterotypic lung infection, viral nucleic acid was undetect-
able with single-step PCR after day 9 (not shown). Others
similarly found that viral nucleic acid is not amplifiable
with single step PCR 2 wk after primary influenza A/X-31
in the lung (27).
In previous work from other groups, CTLs have been
recovered from the brains of animals infected with persis-
tent CNS viruses (28). However, our results indicate that
activated specific antiviral CTLs can persist in the brain
long after viral clearance. Recently, a population of acti-
vated antiviral lymphoblasts was recovered from the spleens
of mice after clearance of systemic lymphocytic chorio-
meningitis virus (LCMV; reference 29). It remains to be
determined if our persistent antiviral CTLs in the CNS are
analogous to this population, but collectively these data in-
dicate that a component of long-term memory may be per-
sistently activated cells at the site of initial infection. If this
Figure 3. (a) CD81 cells puri-
fied from day 7 (early response)
and day 180 (late response) have
a similar activated/memory phe-
notype and CD69 is a better ac-
tivation marker than CD25. (b)
In vivo proliferation of brain
CD81 cells early in the response
to A/WSN. (c) Brain CD81 cells
are not proliferating late in the
response. A representative one of
three experiments is shown. Com-
parison of BRDU uptake by the
splenic and brain CD81CD44hi
populations showed that there
was a 2.9 6 0.17–fold enrich-
ment of BRDU1 cells at day 6 in
the brain compared with a 0.48 6
0.22–fold enrichment at day 180
(mean 6 SEM; P , 0.005 using
an unpaired t test). A significant
reduction in CD81BRDU1 cells
in the late brains compared with
their CD81CD44hi counterparts
was also evident. Quadrant fre-
quencies are shown (%).
Table 3. Summary of PCR Data
Days after
intracranial
challenge
Single-step
NP1/NP2 PCR
Seminested
NP4/NP2 PCR
0 0/5* 0/5
16 5/5 ND
23 5/5 ND
30 0/6 3/6
56 0/3 1/3
115 0/9 3/9
196 0/6 0/6
*Number of positive tests/number of tests performed.
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population is capable of recirculation after LCMV infec-
tion, they may have an important role in immune surveil-
lance in nonlymphoid organs where their state of activation
would favor endothelial transmigration. However, in our
model where systemic infection is minimal, it is more likely
that CTLs recovered from the brain are not recirculating
into it, but given the extreme sensitivity of CTLs (30),
have been retained by persisting specific MHC class I–viral
peptide complexes on neural cells that are below the
threshold of detection by immunohistochemistry. It would
be of interest if the persistence of CTLs specific for influ-
enza virus reflects virus persistence at the DNA level as has
recently been demonstrated for LCMV (31). The persis-
tence of activated CTLs at sites of previous viral infection
may be an important component of the response to virus
recrudescence.
Figure 4. PCR amplification of nucleoprotein cDNA from mouse brain. Numbers refer to day after intracerebral inoculation. M, HaeIII-digested fx
174 markers. R1 is a positive from the NP1/NP2 reaction run for size comparison. Representative gels are shown; each lane represents the result from an
individual mouse. With seminested PCR, nucleoprotein cDNA was amplified from three of nine animals at day 115 and from none of six animals at day
196 (Table 3). Hypoxanthine guanosine phosphoribosyl transferase PCR was positive in all samples indicating that the cDNA synthesis had been satisfac-
tory. PCR products were visualized on 2% agarose ethidium bromide gels under UV light and photographed on Polaroid film.
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